Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management of Infusion Reactions in RRMS Patients Treated with Lemtrada
NCT02205489Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 4 trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Started Oct 2014; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02205489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205489.